All In Biotech

BLA 761269 · Eisai INC

Leqembi

Lecanemab-Irmb · Injection · Amyloid Beta-directed Antibody

NovelBreakthrough therapyAccelerated approvalPriority review

CDER novel approval, Jan 6, 2023: To treat Alzheimer's disease

Last checked: Nov 20, 2026Latest source record: Jan 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Jan 6, 2023

Approved uses

3

Original approval plus efficacy supplements

Registered trials

19

6 Phase 3, 6 recruiting

FAERS reports

3,813

1,660 serious, 164 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: AMYLOID RELATED IMAGING ABNORMALITIES Monoclonal antibodies directed against aggregated forms of beta amyloid, including LEQEMBI, can cause amyloid related imaging abnormalities (ARIA), characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). Incidence and timing of ARIA vary among treatments. ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events can occur. ARIA can be fatal. Serious intracerebral hemorrhage s > 1 cm, some of which have been fatal, have been observed in patients treated with this class of medications. Because ARIA-E can cause focal neurologic deficits that can mimic an ischemic stroke, treating clinicians should consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy to a patient being treated with LEQEMBI [see Warnings and Precautions (...

What it is approved for

From the label in effect Jul 21, 2026.

LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. LEQEMBI is an amyloid beta-directed antibody indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. ( 1 )

Mechanism: Lecanemab-irmb is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer’s disease. LEQEMBI reduces amyloid beta plaques, as evaluated in Study 1 and Study 2 [see Clinical Studies ( 14 )] .

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 24, 2025 Supplement 5 · Efficacy LabelLetter
  • Jul 6, 2023 Supplement 1 · Efficacy · priority review LabelLetterReview
  • Jan 6, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLetterSummary ReviewLabel
2 products under this application
  • LEQEMBI · LECANEMAB-IRMB 200MG/2ML · INJECTABLE, INJECTION · Prescription
  • LEQEMBI · LECANEMAB-IRMB 500MG/5ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Lecanemab" as an intervention, any sponsor and status, largest first.

All 19 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • amyloid related imaging abnormality-oedema/effusion530
  • headache492
  • amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits487
  • infusion related reaction330
  • chills249
  • fatigue225
  • pyrexia179
  • dizziness175
  • confusional state172
  • nausea156
  • cerebral haemorrhage136
  • fall118

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20211
20227
2023263
20241,402
20251,364
2026776

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Leqembi (Lecanemab-Irmb)

2024 spending

$514K

Beneficiaries

48

399 claims

Per beneficiary

$10,714

$136.81 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$17,321
2024$514,268

Part B: Leqembi (Lecanemab-Irmb) · HCPCS J0174

2024 spending

$90.4M

Beneficiaries

7,907

86,149 claims

Per beneficiary

$11,429

2024 ASP limit $1.34 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$4,243,344
2024$90,371,611

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 54 on PubMed

Sponsor: Eisai

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.